Brian Selby Net Worth

The estimated Net Worth of Brian L. Selby is at least $19.1 Mille dollars as of 27 February 2018. Mr. Selby owns over 161 units of ARCA biopharma Inc stock worth over $2,674 and over the last 10 years he sold ABIO stock worth over $16,385. In addition, he makes $0 as Chief Accounting Officer, Principal Accounting Officer e Vice President - Finance at ARCA biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Selby ABIO stock SEC Form 4 insiders trading

Brian has made over 10 trades of the ARCA biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 1,114 units of ABIO stock worth $557 on 2 April 2018.

The largest trade he's ever made was selling 1,125 units of ARCA biopharma Inc stock on 2 March 2015 worth over $799. On average, Brian trades about 456 units every 80 days since 2015. As of 27 February 2018 he still owns at least 1,114 units of ARCA biopharma Inc stock.

You can see the complete history of Mr. Selby stock trades at the bottom of the page.

Brian Selby biography

Brian Selby is Chief Accounting Officer, Vice President - Finance of the Company. Prior to joining ARCA, he worked at several public companies, including Controller for Myogen, Inc. and Controller for Genomica Corporation.

How old is Brian Selby?

Brian Selby is 53, he's been the Chief Accounting Officer, Principal Accounting Officer e Vice President - Finance of ARCA biopharma Inc since 2014. There are 11 older and 1 younger executives at ARCA biopharma Inc. The oldest executive at ARCA biopharma Inc is Dr. Michael R. Bristow M.D., Ph.D., 76, who is the Co-Founder, Pres, CEO & Director.

What's Brian Selby's mailing address?

Brian's mailing address filed with the SEC is 10170 CHURCH RANCH WAY, SUITE 100, WESTMINSTER, CO, 80021.

Insiders trading at ARCA biopharma Inc

Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.

What does ARCA biopharma Inc do?

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.

Complete history of Mr. Selby stock trades at ARCA biopharma Inc

ARCA biopharma Inc executives and stock owners

ARCA biopharma Inc executives and other stock owners filed with the SEC include:

• Michael Bristow,
  President, Chief Executive Officer, Director
• Dr. Michael R. Bristow M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Thomas A. Keuer,
  Chief Operating Officer
• Christopher Ozeroff,
  Senior Vice President, General Counsel, Secretary
• Christopher D. Ozeroff,
  Sr. VP, Gen. Counsel & Sec.
• Raymond Woosley,
  Director
• Daniel Mitchell,
  Director
• Anders Hove,
  Director
• Linda Grais,
  Lead Independent Director
• Brian Selby,
  Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
• Thomas Keuer,
  Chief Operating Officer
• Robert Conway,
  Chairman of the Board
• Dr. Debra Marshall FACC, M.D.,
  Chief Medical Officer
• C. Jeffrey Dekker,
  Chief Financial Officer
• Henderson Group Plc Janus H...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Healthcare Capital Partners...,
  
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• Equity Opportunities Fund I...,
  
• Jean Francois Formela,
  Director
• Kathryn E Falberg,
  CFO and COO
• J William Freytag,
  Director
• Mary K Pendergast,
  Director
• Patrick M Wheeler,
  acting Chief Financial Officer
• Riley Mccormack,
  10% owner
• David George Lowe,
  Director
• Burton E Sobel,
  Director
• Venture Fund Vii L P Atlas,
  10% owner
• Richard B Brewer,
  Director
• John L Zabriskie,
  Director
• Venture Partners Qualified ...,
  10% owner
• Ted W Love,
  Director
• Funds, Lp Ma Weaver Jacob F...,
  
• Jacob Ma Weaver,
  
• Fund, Lp Funicular,
  
• C. Jeffrey Dekker,
  Chief Financial Officer
• Fund, Lp Ma Weaver Jacob Fu...,
  
• Funds, Lp Funicular,
  10% owner
• James P Flynn,
  Director